ISSN : 2393-8862
Acute promyelocytic leukemia is a distinct subtype of acute myelocytic leukemia. It has distinct genetic and molecular profile than other acute leukemia subtypes. Due to its distinct molecular signature, the chemotherapeutic regimens utilized bear distinct treatment protocols. Various chemotherapeutic agents used include all-trans-retinoic acid, arsenic trioxide and taxanes. Recently, immunotherapy has been implored as a possible treatment protocol but with limited success.